So happy to see my global health onc friends!! Ayo S Falade, MD, MBA, APGD Tayo Adeoye Dayo Fadelu at #ASCO2025 !! ASCO Dana-Farber Center for Global Cancer Medicine #IMGPower 😎

So good to see my dear friend who is becoming the best thoracic oncologist in Boston! Mary Boulanger So proud of you!!! You rock!!! #ASCO2025 ASCO !!! Eres lo maximoooo! #Hemeonc sisterhood 😎💕😏 Women in Oncology

Chicago you are so perfect. I am incredibly grateful of working here 🤗☺️☑️

Thrombosis risk in MPN patients peaks within 2 years of diagnosis and is later driven by age. This nationwide study highlights the need for early management and age-specific care to optimise outcomes. buff.ly/SdEag9q

As a former J1 visa physician I was very happy to hear these news ! 😩🫶🙌🤯✌🏻🥺🫶

Job alert! If you're passionate about making a difference and ready for your next career move, explore exciting opportunities now available through our network. #HTRS #NowHiring #CareerOpportunity Learn more and apply today: htrs.org/career-develop…

🔍 Thrombophilia testing? Knowing when and how to test is crucial — but so is knowing which lab to trust. The latest ISTH SSC guidance outlines best practices and recommendations for lab selection and testing reliability. Read it👇Share it Apply it #ISTH2025 #Hemostasis

Is this the end of rivaroxaban for acute VTE? Lana Castellucci presenting the COBBRA trial - 1st RCT comparing apixaban to riva over 3 months. 56% reduction in bleeding risk with apixaban. A safer Rx with the same efficacy. #ISTH2025

📢 Practice-changing data from the Adjust-DVT study! ✅ Age-adjusted D-dimer safely rules out DVT in low/non-high pretest probability patients 📉 Reduces unnecessary ultrasounds 🔍 +17% yield in patients ≥75 years #ISTH2025 #DVT #Thrombosis #LessIsMore

Do you dose reduce DOAC for extended prevention of VTE? 💙 Post hoc analysis of RENOVE trial of secondary prevention of VTE. ♥️ suggests low dose DOAC may be inferior to full dose among people with BMI >30. 💙 more data is needed #ISTH2025

Perks of working as a #classical #nonmalignant #hematologist in Chicago? Go to Chinatown after a busy consults day 😁😇😎 #peruviandoc 🇵🇪 🇺🇸 Hem-Onc Fellows Network

2025 ASH ISTH NBDF WFH monitoring report on the 2021 clinical #guidelines on the diagnosis and management of von #Willebrand disease. none of the reviewed studies would change the direction or strength of the existing guideline recommendations ashpublications.org/bloodadvances/…

🚀 How to better understand and explain gene therapy of haemophilia? Our latest publication, "Gene-based therapies for hemophilia," is now available as full-open access article in Research and Practice in Thrombosis and Haemostasis! This illustrated review provides a

Rather than being impressed by wealth, status, or titles, it's more important to value kindness, integrity, and humility.

“Don’t let yesterday take up too much of today.” ~ Cherokee,

Working in Chicago as a #classical #nonmalignant hematologist means going to have a parrilla argentina & empanadas for dinner. LOVE this city. Viva Sudamerica ❤️‍🔥

Excellent "How I manage pregnant patients who are alloimmunized to RBC antigens" in Blood recently.